Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-023294
Filing Date
2017-11-09
Accepted
2017-11-09 16:41:34
Documents
55
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q eigr-10q_20170930.htm 10-Q 1626553
2 EX-31.1 eigr-ex311_7.htm EX-31.1 16844
3 EX-31.2 eigr-ex312_6.htm EX-31.2 16905
4 EX-32.1 eigr-ex321_8.htm EX-32.1 5745
  Complete submission text file 0001564590-17-023294.txt   5499578

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT eigr-20170930.xml EX-101.INS 1197272
6 XBRL TAXONOMY EXTENSION SCHEMA eigr-20170930.xsd EX-101.SCH 41285
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eigr-20170930_cal.xml EX-101.CAL 35696
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eigr-20170930_def.xml EX-101.DEF 151133
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20170930_lab.xml EX-101.LAB 307056
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20170930_pre.xml EX-101.PRE 237477
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

EIN.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 171191439
SIC: 2836 Biological Products, (No Diagnostic Substances)